MetaVia (MTVA) reported additional top-line results from the multiple ascending dose Part 2 of its Phase 1 clinical trial of DA-1726, a novel, dual oxyntomodulin analog agonist that functions as a ...
The MARITIME Phase 3 Chronic Weight Management Studies are Actively Enrolling, and Phase 3 Studies in People Living With Atherosclerotic Cardiovascular Disease, Heart Failure and Obstructive Sleep ...
Novo Nordisk has abandoned another GLP-1/GIP co-agonist and CB1 receptor as part of a significant pipeline clearout that coincides with disappointing obesity sales and a leadership shake-up. The ...
Retatrutide (LY3437943) is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors. Its dose–response relationships with respect to side effects ...
No Significant Issues Encountered During the Single Ascending Dose (SAD) Study, Allowing for Previously Reported Accelerated Start to Multiple Ascending Dose (MAD) Part 2 Top Line Data Readout from ...
Three UAB studies look at obesity in-utero and how it affects offspring as part of four-center study
A new study, published in the Journal of the American Heart Association, suggests that what happens in the womb could determine whether the offspring will develop obesity or other metabolic diseases ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback